Search results

2020 has been quite a year! Each year, we strive to provide you with a more innovative, simplified, and seamless early phase drug development journey. And the past 12 months have been no exception.

Hallucinogens, dissociatives and other Schedule I drugs are increasingly being found to have a clinical application in a number of therapeutic areas. Recent approvals, background, and related case studies in this month's blog.

Ensuring that current and relevant FDA and EMA guidances are applied to the handling of bioanalytical samples during clinical trial conduct is crucial. This month's blog, including podcast, offers an expert look at the considerations.